Hims & Hers Health, Inc. (HIMS) Stock: Peptides+ Launch Expands Healthcare Services

Nov 19, 2026 - 02:17
0 1
Hims & Hers Health, Inc. (HIMS) Stock: Peptides+ Launch Expands Healthcare Services

TLDR

  • HIMS stock falls 2.93% to $17.04 despite the launch of its Peptides+ service.
  • Peptides+ debuts with five treatments guided by licensed medical providers.
  • Hims & Hers adds cellular health services to its growing telehealth platform.
  • Care+ offers twice-yearly lab tests and ongoing support from medical teams.
  • Hims & Hers plans to add BPC-157 and TB-500 under applicable U.S. regulations.

Hims & Hers Health, Inc. (NYSE: HIMS) has launched Peptides+, expanding its personalized healthcare services into cellular health and wellness. The new specialty offers five treatments through licensed medical providers, with additional therapies planned under regulatory requirements. Meanwhile, HIMS stock declined 2.93% to $17.04, losing $0.51 as selling pressure continued during afternoon trading.


HIMS Stock Card

Hims & Hers Health, Inc., HIMS

Hims & Hers Introduces Five Treatments Through Peptides+

Hims & Hers introduced Peptides+ on November 18, expanding its telehealth platform beyond its existing treatment categories. The service combines personalized treatment plans with clinical assessments and ongoing support from licensed healthcare professionals. Furthermore, the company aims to improve access to emerging therapies through its established digital healthcare network.

At launch, Peptides+ offers Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine through licensed U.S. compounding pharmacies. Sermorelin supports growth hormone signaling, while NAD+ plays a role in cellular energy production and DNA repair. Additionally, Glutathione supports antioxidant functions, while Vitamin B12 and L-Carnitine contribute to normal metabolic processes.

Customers must complete a medical assessment before providers determine their eligibility for any available treatment. Providers review medical histories, health conditions, and individual goals before developing appropriate treatment plans. Subsequently, care teams monitor patient progress and adjust treatment protocols according to clinical needs and individual responses.

Care+ Adds Lab Testing and Personalized Medical Support

The Peptides+ specialty operates alongside Care+, which combines healthcare treatments with laboratory testing and ongoing medical guidance. Under this program, eligible customers receive laboratory testing twice annually and access to dedicated healthcare support teams. Moreover, the service allows customers to contact providers trained in peptide therapies through continuous messaging access.

For men, the Hims health panel provides at-home blood collection and testing across 22 health biomarkers. These measurements include testosterone, cholesterol, and vitamin D levels, offering additional information about individual health conditions. Customers with relevant laboratory results can also consult providers about potential eligibility for testosterone treatment.

Meanwhile, Hers has introduced an at-home blood collection option for women through its dedicated health panel. The service measures 22 biomarkers covering hormone levels, vitamin status, and cardiovascular health indicators. Consequently, the company has expanded its laboratory services while integrating additional testing into its personalized healthcare platform.

Hims & Hers Plans Further Expansion of Peptides+ Services

Hims & Hers plans to introduce BPC-157 and TB-500 as its Peptides+ specialty expands beyond its initial offerings. However, the company intends to align access to these treatments with applicable regulatory standards. The planned additions represent another stage in its expansion into emerging healthcare treatment categories.

The company currently provides telehealth services across several categories, including dermatology, sexual health, and weight management. Peptides+ adds another specialty to this model by combining remote consultations, treatment delivery, and medical follow-up services. Furthermore, licensed U.S. pharmacies will compound and dispense prescribed treatments under applicable state pharmacy regulations.

The launch also expands the company’s focus on personalized healthcare through laboratory insights and provider-led treatment decisions. Its integrated approach connects medical assessments, testing, prescriptions, and ongoing patient communication within one digital platform. As a result, Peptides+ broadens Hims & Hers’ service portfolio while supporting its expansion across additional healthcare categories.

 

The post Hims & Hers Health, Inc. (HIMS) Stock: Peptides+ Launch Expands Healthcare Services appeared first on Blockonomi.

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Wow Wow 0
Sad Sad 0
Angry Angry 0

Comments (0)

User